Press Release - February 8, 2017
Heidelberg, Germany, February 8, 2017 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 9:00 a.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the Webcast section on the Affimed website. A replay of the presentation will be available from Affimed’s website for 30 days following the respective conference.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347 394 6793
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341